CRISPR-Cas9–based treatment of myocilin-associated glaucoma

Keyphrases

• Glaucoma 100%
• Myocilin 100%
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 100%
• Primary Open-angle Glaucoma 60%
• Endoplasmic Reticulum Stress (ER stress) 40%
• Intraocular Pressure 20%
• Elevated Intraocular Pressure 20%
• Trabecular Meshwork 20%
• Glaucomatous 20%
• Mouse Model 20%
• Trabecular Meshwork Cells 20%
• Vision Loss 20%
• In Vivo Genome Editing 20%
• Organ Culture System 20%
• Knock 20%
• Major Risk Factors 20%
• Human Genome Editing 20%
• Gain-of-function mutation 20%
• Genome Editing 20%
• Protein Misfolding 20%
• Human Organ Culture 20%
• Low Intraocular Pressure 20%

Medicine and Dentistry

• Glaucoma 100%
• Clustered Regularly Interspaced Short Palindromic Repeat 100%
• Myocilin 100%
• Intraocular Pressure 60%
• Genome Editing 60%
• Open Angle Glaucoma 60%
• Trabecular Meshwork 40%
• Endoplasmic Reticulum Stress 40%
• Disease 20%
• Ex Vivo 20%
• Visual Impairment 20%
• Human Genome 20%
• Organ Culture 20%
• Protein Misfolding 20%
• Gain of Function Mutation 20%

Biochemistry, Genetics and Molecular Biology

• Intraocular Pressure 100%
• Genome Editing 100%
• CRISPR 100%
• Endoplasmic Reticulum Stress 66%
• Mouse Model 33%
• Organ Culture 33%
• Gain of Function Mutation 33%
• Protein Misfolding 33%
• Human Genome 33%